Currently, users attempting to submit a TRACE or Over the Counter Reporting Facility (ORF) form may incur an error. Users may also have issues accessing Participant Data Management.
Firms should contact FINRA Market Operations or call (866) 776-0800 with questions or for assistance in setting up new issues. FINRA will advise when this issue has been resolved.
Options are complex instruments that can play a number of different roles within an investment portfolio, but buying and selling options can be risky, and trading the products requires specific approval from an investor’s brokerage firm. Equity options are derivative contracts that give the purchaser the right, and the seller the obligation, to buy or sell, a security at a fixed price within a specific period of time.
Investing in commodities is a way to potentially add diversification to an investment portfolio. Commodities, commodity futures, and related mutual funds and exchange-traded products offer opportunities to investors seeking to gain exposure to this asset class.
We are a firm of 3 people, it will be impossible for us to be able to report ANY BONDS in a 1 minute time frame. I feel that at the minimum it should 10 mins, anything shorter than that and we would probably be reporting late on a consistent basis.
Three Supervisors Suspended for Failing to Respond to Red Flags Eight Representatives Suspended for Excessive Trading
WASHINGTON—FINRA announced today that it has ordered Joseph Stone Capital LLC to pay restitution of approximately $825,000 to customers whose accounts were excessively traded by the firm’s representatives. In related settlements, FINRA suspended eight current or former Joseph
FINRA experienced an issue this morning with the processing of Monthly OTC Transparency Data, thereby causing a publication delay for the month of July 2022 Non-ATS monthly data and ATS and Non-ATS Block data on the OTC Transparency Data website.
The issue has now been resolved and all files and data have been published on the website.
If you have any questions, please contact ATS Support.
FINRA experienced an issue this morning with the processing of Monthly OTC Transparency Data, thereby causing a publication delay for the month of July 2022 Non-ATS monthly data and ATS and Non-ATS Block data on the OTC Transparency Data website. FINRA is working on resolving the issue and will provide an update once the issue is resolved.
If you have any questions, please contact ATS Support.
